ArticleVeterinary research2025
Protective effect of heat-inactivated Mycobacterium bovis applied intramuscularly is associated with enhanced lung immune response in caprine tuberculosis.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Caprine tuberculosis (TB) causes a zoonotic disease with significant economic and health implications. However, excluding some regions, goat herds are not subjected to official TB eradication programs. Implementing vaccination protocols for this species could provide a complementary and effective control strategy against TB. We assessed the protective efficacy and immune response associated with a heat-inactivated Mycobacterium bovis (M. bovis)-based immunostimulant (HIMB) applied intramuscularly against caprine pulmonary TB on 20 kid goats (10 immunized, 10 controls) naturally exposed to M. caprae infected goats for 10 months. TB-compatible lung lesions were assessed, alongside a local immune response analysis by immunohistochemistry of cell populations (Macrophages (MΦs), neutrophils, T, and B lymphocytes) and associated immune mediators (iNOS, TNF-α, IL-1α, IL-6, IFN-γ, TGF-β, IL-4). In the control group, 60% of the animals showed TB compatible lesions, compared with 40% of the immunized animals, which also showed a 78% reduction (p = 0.03) in the lesion severity score. Moreover, immunized animals showed a higher number of M1 MΦs (p = 0.03), producers of iNOS, as well as a higher expression of TNFα (p = 0.04) and IL-1α (p = 0.03). These mediators play a key role in the activation of a Th1-type cellular immune responses effective against mycobacteria, associated with a response of T lymphocytes expressing IFNγ, whose response was increased in the immunized group (p = 0.05). These results suggest that immunization with HIMB reduced the number and severity of TB-associated pulmonary lesions, which could be linked with an enhanced production of immune mediators with an essential role in the activation of MΦs with bactericidal functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.